OpGen to Receive Ignaz Semmelweis Award for Commitment to Combatting Infection Deaths
May 30, 2017 12:08 pm UTC| Business
GAITHERSBURG, Md., May 30, 2017 -- OpGen, Inc. (NASDAQ:OPGN) announced today that they will be recognized with the 2nd annual Ignaz Semmelweis Award for their commitment to safe medical care through the development of...
OpGen to Receive Ignaz Semmelweis Award for Commitment to Combatting Infection Deaths
May 30, 2017 12:08 pm UTC| Business
GAITHERSBURG, Md., May 30, 2017 -- OpGen, Inc. (NASDAQ:OPGN) announced today that they will be recognized with the 2nd annual Ignaz Semmelweis Award for their commitment to safe medical care through the development of...
OpGen to Receive Ignaz Semmelweis Award for Commitment to Combatting Infection Deaths
May 30, 2017 12:08 pm UTC| Business
GAITHERSBURG, Md., May 30, 2017 -- OpGen, Inc. (NASDAQ:OPGN) announced today that they will be recognized with the 2nd annual Ignaz Semmelweis Award for their commitment to safe medical care through the development of...
OpGen to Receive Ignaz Semmelweis Award for Commitment to Combatting Infection Deaths
May 30, 2017 12:08 pm UTC| Business
GAITHERSBURG, Md., May 30, 2017 -- OpGen, Inc. (NASDAQ:OPGN) announced today that they will be recognized with the 2nd annual Ignaz Semmelweis Award for their commitment to safe medical care through the development of...
May 30, 2017 12:07 pm UTC| Business
RESEARCH TRIANGLE PARK, N.C., May 30, 2017 -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a clinical-stage oncology company, today announced that Phase 1b data from the ongoing Phase 1b/2a study of its lead CDK4/6 inhibitor...
May 30, 2017 12:07 pm UTC| Business
RESEARCH TRIANGLE PARK, N.C., May 30, 2017 -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a clinical-stage oncology company, today announced that Phase 1b data from the ongoing Phase 1b/2a study of its lead CDK4/6 inhibitor...
May 30, 2017 12:07 pm UTC| Business
RESEARCH TRIANGLE PARK, N.C., May 30, 2017 -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a clinical-stage oncology company, today announced that Phase 1b data from the ongoing Phase 1b/2a study of its lead CDK4/6 inhibitor...